Clinical trials: Imipenem
Antibacterial Prophylaxis, Hematological Malignancies
Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematologic malignancies.
- Conditions
- Antibacterial Prophylaxis, Hematological Malignancies, Allogenetic Hematopoietic Stem Cell Transplantation, Imipenem
- Trial name
- NCT03733340
- Testing
- Imipenem
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Febrile, Neutropenia
Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia
Neutropenia is very common in patients received hematopoietic stem cell transplantation, with median duration of about 14 days. In 2010 update, IDSA recommended Piperacillin/tazobactam as first-line mono-therapy for febrile…
- Conditions
- Febrile, Neutropenia, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT01714570
- Testing
- Piperacillin-tazobactam combination product, Imipenem
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Chinese PLA General Hospital
Lung Transplantation
Pharmacokinetics of Imipenem During Ex Vivo Lung Perfusion (EVLP)
Ex vivo lung perfusion (EVLP) is an established strategy to evaluate and optimize high-risk donor lungs that would otherwise be rejected for transplantation mainly due to the presence of edema or infection.
- Trial name
- NCT02670239
- Testing
- normothermic ex vivo lung perfusion
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy
Gram Negative Organism
Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC
The isolate samples will be collected over a period of one year once IRB approval has been obtained. These isolates were collected as part of the patient's clinical care and once all clinical testing is complete, all isolates…
- Trial name
- NCT00443885
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- University of Pittsburgh
Skin Infection, Abscess
Complicated Skin and Skin Structure Infections
The purpose of this study is to demonstrate the non-inferiority of meropenem (Merrem) and imipenem in hospitalised subjects with complicated skin and skin structure infections.
- Conditions
- Skin Infection, Abscess, Cellulitis
- Trial name
- NCT00619710
- Testing
- Meropenem, Imipenem-cilastatin
- Volunteers
- 1,000 people
- Sponsor
- Pfizer
Cystic Fibrosis, Pneumonia, Bacterial
Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis
There is established evidence that patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients.
- Trial name
- NCT05561764
- Testing
- Imipenem/Cilastatin/Relebactam
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Hartford Hospital
Gram-Positive Bacterial Infections, Cross Infection
Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects
Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.
- Trial name
- NCT00081744
- Testing
- Tigecycline
- Volunteers
- 850 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Multi-antibiotic Resistance
Use of New Antibiotics in Sweden
Antibiotic resistance is a growing global health problem of great concern, especially multidrug-resistant Gram-negative bacteria. In recent years some new antibiotics targeting these bacteria have been developed.
- Trial name
- NCT05048693
- Where
- 7 sites in Sweden
- Volunteers
- 41 people
- Sponsor
- Uppsala University
Suspected or Documented Gram-negative Bacterial Infection
Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
The primary purpose of this study is to evaluate the safety and tolerability of imipenem/cilastatin/relebactam (IMI/REL) in participants from birth to less than 18 years of age with confirmed or suspected gram-negative bacterial…
- Trial name
- NCT03969901
- Testing
- IMI/REL, Active Control, Oral Switch
- Where
- 67 sites in United States, Bulgaria and 16 more
- Volunteers
- 115 people
- Sponsor
- Merck Sharp & Dohme LLC